Base de dados : MEDLINE
Pesquisa : B04.820.650.589.650.350 [Categoria DeCS]
Referências encontradas : 17474 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1748 ir para página                         

  1 / 17474 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29373606
[Au] Autor:Devadas K; Biswas S; Ragupathy V; Lee S; Dayton A; Hewlett I
[Ad] Endereço:Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America.
[Ti] Título:Modulation of HIV replication in monocyte derived macrophages (MDM) by steroid hormones.
[So] Source:PLoS One;13(1):e0191916, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Significant sex specific differences in the progression of HIV/AIDS have been reported. Several studies have implicated steroid hormones in regulating host factor expression and modulating HIV transmission and replication. However, the exact mechanism exerted by steroid hormones estrogen and progesterone in the regulation of HIV-1 replication is still unclear. Results from the current study indicated a dose dependent down regulation of HIV-1 replication in monocyte derived macrophages pre-treated with high concentrations of estrogen or progesterone. To elucidate the molecular mechanisms associated with the down regulation of HIV-1 replication by estrogen and progesterone we used PCR arrays to analyze the expression profile of host genes involved in antiviral responses. Several chemokines, cytokines, transcription factors, interferon stimulated genes and genes involved in type-1 interferon signaling were down regulated in cells infected with HIV-1 pre-treated with high concentrations of estrogen or progesterone compared to untreated HIV-1 infected cells or HIV-1 infected cells treated with low concentrations of estrogen or progesterone. The down regulation of CXCL9, CXCL10 and CXCL11 chemokines and IL-1ß, IL-6 cytokines in response to high concentrations of estrogen and progesterone pre-treatment in HIV-1 infected cells was confirmed at the protein level by quantitating chemokine and cytokine concentrations in the culture supernatant. These results demonstrate that a potent anti-inflammatory response is mediated by pre-treatment with high concentrations of estrogen and progesterone. Thus, our study suggests a strong correlation between the down-modulation of anti-viral and pro-inflammatory responses mediated by estrogen and progesterone pre-treatment and the down regulation of HIV-1 replication. These findings may be relevant to clinical observations of sex specific differences in patient populations and point to the need for further investigation.
[Mh] Termos MeSH primário: Estrogênios/fisiologia
HIV/fisiologia
Macrófagos/virologia
Progesterona/fisiologia
Replicação Viral
[Mh] Termos MeSH secundário: Seres Humanos
Reação em Cadeia da Polimerase
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Estrogens); 4G7DS2Q64Y (Progesterone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180127
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191916


  2 / 17474 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27774620
[Au] Autor:Vendramin C; McGuckin S; Alwan F; Westwood JP; Thomas M; Scully M
[Ad] Endereço:Department of Haematology, University College London Hospital.
[Ti] Título:A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy.
[So] Source:Transfusion;57(1):131-136, 2017 01.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients presenting with acute episodes of thrombotic microangiopathies (TMAs) require urgent access to plasma exchange (PEX). OctaplasLG, a solvent/detergent fresh-frozen plasma product that has undergone viral inactivation and prion reduction step, has been used in our institution since 2013, replacing Octaplas. STUDY DESIGN AND METHODS: We prospectively reviewed 981 PEX procedures where OctaplasLG was the replacement fluid in 90 patients admitted acutely with a TMA presentation within our institution from January 1, 2013, to December 31, 2015. We recorded citrate toxicities, plasma reactions, viral transfer, complications related to central venous catheter, and venous thrombotic events (VTEs). RESULTS: Citrate toxicities were 5.4%, plasma reactions were 2%, and all were classified as Grade 1 or 2. VTE had an incidence of 12.2%, although 50% of the episodes occurred in early remission when patients were not receiving PEX. No line insertions complications were recorded. Line-associated infections were 2.2%. Hepatitis B and C serology and human immunodeficiency virus (HIV) were checked on admission. There were four patients who may have had passive transient transfer of hepatitis B antibodies from pooled plasma. No hepatitis C or HIV viral transfer was documented after treatment and no seroconversion was detected after treatment. CONCLUSION: Our data have demonstrated that the incidence of complications during PEX is low and using OctaplasLG is comparable to the low incidence of reactions. No cases of anaphylaxis, transfusion-related acute lung injury, or fatal plasma reactions were seen. There was no evidence of viral transmission or seroconversion after treatment.
[Mh] Termos MeSH primário: Desinfecção/métodos
Troca Plasmática/métodos
Plasma
Príons
Microangiopatias Trombóticas/terapia
Inativação de Vírus
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Detergentes/química
Feminino
HIV
Infecções por HIV/prevenção & controle
Hepacivirus
Hepatite B/prevenção & controle
Vírus da Hepatite B
Hepatite C/prevenção & controle
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Solventes/química
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Detergents); 0 (Prions); 0 (Solvents)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1111/trf.13877


  3 / 17474 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29324338
[Au] Autor:Gamba E; Mori M; Kovalenko L; Giannini A; Sosic A; Saladini F; Fabris D; Mély Y; Gatto B; Botta M
[Ad] Endereço:Dipartimento di Scienze del Farmaco, Università di Padova, via Marzolo 5, 35131 Padova, Italy.
[Ti] Título:Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1 nucleocapsid protein.
[So] Source:Eur J Med Chem;145:154-164, 2018 Feb 10.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:In this report, we present a new benzoxazole derivative endowed with inhibitory activity against the HIV-1 nucleocapsid protein (NC). NC is a 55-residue basic protein with nucleic acid chaperone properties, which has emerged as a novel and potential pharmacological target against HIV-1. In the pursuit of novel NC-inhibitor chemotypes, we performed virtual screening and in vitro biological evaluation of a large library of chemical entities. We found that compounds sharing a benzoxazolinone moiety displayed putative inhibitory properties, which we further investigated by considering a series of chemical analogues. This approach provided valuable information on the structure-activity relationships of these compounds and, in the process, demonstrated that their anti-NC activity could be finely tuned by the addition of specific substituents to the initial benzoxazolinone scaffold. This study represents the starting point for the possible development of a new class of antiretroviral agents targeting the HIV-1 NC protein.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/farmacologia
Benzoxazóis/farmacologia
HIV/efeitos dos fármacos
Proteínas do Nucleocapsídeo/antagonistas & inibidores
[Mh] Termos MeSH secundário: Fármacos Anti-HIV/síntese química
Fármacos Anti-HIV/química
Benzoxazóis/síntese química
Benzoxazóis/química
Relação Dose-Resposta a Droga
Testes de Sensibilidade Microbiana
Estrutura Molecular
Proteínas do Nucleocapsídeo/metabolismo
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Benzoxazoles); 0 (Nucleocapsid Proteins); 3X996Q809V (benzoxazolone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE


  4 / 17474 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29360873
[Au] Autor:Xu SX; Leontyev D; Kaul R; Gray-Owen SD
[Ad] Endereço:Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
[Ti] Título:Neisseria gonorrhoeae co-infection exacerbates vaginal HIV shedding without affecting systemic viral loads in human CD34+ engrafted mice.
[So] Source:PLoS One;13(1):e0191672, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:HIV synergy with sexually transmitted co-infections is well-documented in the clinic. Co-infection with Neisseria gonorrhoeae in particular, increases genital HIV shedding and mucosal transmission. However, no animal model of co-infection currently exists to directly explore this relationship or to bridge the gap in understanding between clinical and in vitro studies of this interaction. This study aims to test the feasibility of using a humanized mouse model to overcome this barrier. Combining recent in vivo modelling advancements in both HIV and gonococcal research, we developed a co-infection model by engrafting immunodeficient NSG mice with human CD34+ hematopoietic stem cells to generate humanized mice that permit both systemic HIV infection and genital N. gonorrhoeae infection. Systemic plasma and vaginal lavage titres of HIV were measured in order to assess the impact of gonococcal challenge on viral plasma titres and genital shedding. Engrafted mice showed human CD45+ leukocyte repopulation in blood and mucosal tissues. Systemic HIV challenge resulted in 104-105 copies/mL of viral RNA in blood by week 4 post-infection, as well as vaginal shedding of virus. Subsequent gonococcal challenge resulted in unchanged plasma HIV levels but higher viral shedding in the genital tract, which reflects published clinical observations. Thus, human CD34+ stem cell-transplanted NSG mice represent an experimentally tractable animal model in which to study HIV shedding during gonococcal co-infection, allowing dissection of molecular and immunological interactions between these pathogens, and providing a platform to assess future therapeutics aimed at reducing HIV transmission.
[Mh] Termos MeSH primário: Antígenos CD34/imunologia
Gonorreia/complicações
Infecções por HIV/complicações
HIV/fisiologia
Neisseria gonorrhoeae/isolamento & purificação
Vagina/virologia
Carga Viral
Eliminação de Partículas Virais
[Mh] Termos MeSH secundário: Animais
Feminino
Infecções por HIV/virologia
Seres Humanos
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, CD34)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191672


  5 / 17474 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29229609
[Au] Autor:Desai M; Field N; Grant R; McCormack S
[Ad] Endereço:HIV and STI Department, Public Health England, London NW9 5EQ, UK.
[Ti] Título:Recent advances in pre-exposure prophylaxis for HIV.
[So] Source:BMJ;359:j5011, 2017 12 11.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Although pre-exposure prophylaxis (PrEP)-the use of antiretroviral drugs by non-infected people to prevent the acquisition of HIV-is a promising preventive option, important public health questions remain. Daily oral emtricitabine (FTC)-tenofovir disoproxil fumarate (TDF) is highly efficacious in preventing the acquisition of HIV in people at risk as a result of a range of different types of sexual exposure. There is good evidence of efficacy in women and men, and when men who have sex with men use event based dosing. Studies have been conducted in several countries and epidemics. Because adherence to this treatment varies greatly there are questions about its public health benefit. Oral FTC-TDF is extremely safe, with minimal impact on kidney, bone, or pregnancy outcomes, and there is no evidence that its effectiveness has been reduced by risk compensation during open label and programmatic follow-up. It is too early to assess the impact of this treatment on the incidence of sexually transmitted infections (STIs) at a population level. Many challenges remain. Access to pre-exposure prophylaxis is limited and disparities exist, including those governed by race and sex. Different pricing and access models need to be explored to avoid further widening inequalities. The optimal combination prevention program needs to be defined, and this will depend on local epidemiology, service provision, and cost effectiveness. This review updates the evidence base for pre-exposure prophylaxis regarding its effectiveness, safety, and risk compensation.
[Mh] Termos MeSH primário: Antirretrovirais/uso terapêutico
Combinação Emtricitabina e Fumarato de Tenofovir Desoproxila/uso terapêutico
Infecções por HIV/prevenção & controle
HIV/efeitos dos fármacos
Profilaxia Pré-Exposição/métodos
Doenças Sexualmente Transmissíveis/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antirretrovirais/administração & dosagem
Análise Custo-Benefício
Combinação Emtricitabina e Fumarato de Tenofovir Desoproxila/administração & dosagem
Feminino
HIV/isolamento & purificação
Infecções por HIV/epidemiologia
Infecções por HIV/virologia
Disparidades em Assistência à Saúde
Homossexualidade Masculina/psicologia
Seres Humanos
Incidência
Masculino
Meia-Idade
Ensaios Clínicos Controlados Aleatórios como Assunto
Assunção de Riscos
Doenças Sexualmente Transmissíveis/tratamento farmacológico
Doenças Sexualmente Transmissíveis/prevenção & controle
Cooperação e Adesão ao Tratamento
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Retroviral Agents); 0 (Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5011


  6 / 17474 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29323846
[Au] Autor:Nosik NN; Nosik DN; Chizhov AI
[Ti] Título:A comparative analysis of virucidal efficiency of biocide agents.
[So] Source:Vopr Virusol;62(1):41-5, 2017.
[Is] ISSN:0507-4088
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:The main groups of biocide agents used for inactivation of bacteria and viruses were studied for their virucidal activity against enveloped (HIV, viral hepatitis C, influenza virus A) and non-enveloped viruses (poliovirus, adenovirus). Their efficiency was analyzed. Quarterly ammonium compounds (QAC) themselves are not able to properly inactivate non-enveloped viruses. However, they can be successfully applied in combination with other biocides (guanidines, aldehydes). Effective composition of QAC with amines and guanidines provided inactivation of viruses (4.0 lgTCID50) in concentrations of 0.166-0.280% for non-enveloped viruses and 0.080-00.185% for enveloped viruses. The combination of QAC with aldehydes is especially effective (0.04-0.64% for non-enveloped viruses). The virucidal efficiency does not directly depend on the QAC concentration in the chemical disinfectants.
[Mh] Termos MeSH primário: Aldeídos/farmacologia
Desinfetantes/farmacologia
Guanidinas/farmacologia
Compostos de Amônio Quaternário/farmacologia
Inativação de Vírus
[Mh] Termos MeSH secundário: Adenoviridae/efeitos dos fármacos
Adenoviridae/fisiologia
Aldeídos/química
Desinfetantes/química
Guanidinas/química
HIV/efeitos dos fármacos
HIV/fisiologia
Hepacivirus/efeitos dos fármacos
Hepacivirus/fisiologia
Vírus da Influenza A/efeitos dos fármacos
Vírus da Influenza A/fisiologia
Poliovirus/efeitos dos fármacos
Poliovirus/fisiologia
Compostos de Amônio Quaternário/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aldehydes); 0 (Disinfectants); 0 (Guanidines); 0 (Quaternary Ammonium Compounds)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE


  7 / 17474 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29323840
[Au] Autor:Galegov GA
[Ti] Título:Phosphazide (nikavir) is a highly effective drug for the treatment of HIV/AIDS infection.
[So] Source:Vopr Virusol;62(1):5-11, 2017.
[Is] ISSN:0507-4088
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:Federation Convincing evidence for high therapeutic activity and tolerability of Phosphazide in the treatment of HIV/AIDS-infection is given. Phosphazide is currently used in various regimens of highly active antiretroviral therapy, as well as in the HIV therapy in patients with simultaneously acquired chronic hepatitis C or tuberculosis. Therapeutic possibilities of Phosphazide were clearly manifested in the prevention of HIV transmission from mother to child. There is every reason to use Phosphazide in first-line antiretroviral therapy.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/uso terapêutico
Infecções por HIV/tratamento farmacológico
HIV/efeitos dos fármacos
Transmissão Vertical de Doença Infecciosa/prevenção & controle
Organofosfonatos/uso terapêutico
Complicações Infecciosas na Gravidez/tratamento farmacológico
Zidovudina/análogos & derivados
[Mh] Termos MeSH secundário: Fármacos Anti-HIV/farmacocinética
Terapia Antirretroviral de Alta Atividade/métodos
Feminino
Feto
HIV/genética
HIV/metabolismo
Infecções por HIV/transmissão
Infecções por HIV/virologia
Seres Humanos
Organofosfonatos/farmacocinética
Gravidez
Complicações Infecciosas na Gravidez/virologia
Resultado do Tratamento
Zidovudina/farmacocinética
Zidovudina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (3'-azido-2',3'-dideoxythymidine 5'-H-phoshonate); 0 (Anti-HIV Agents); 0 (Organophosphonates); 4B9XT59T7S (Zidovudine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE


  8 / 17474 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29207000
[Au] Autor:Wallis CL; Godfrey C; Fitzgibbon JE; Mellors JW
[Ad] Endereço:Bio Analytical Research Corporation-South Africa and Lancet Laboratories, Johannesburg, South Africa.
[Ti] Título:Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.
[So] Source:J Infect Dis;216(suppl_9):S851-S856, 2017 Dec 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The emergence and spread of human immunodeficiency virus (HIV) drug resistance from antiretroviral roll-out programs remain a threat to long-term control of the HIV-AIDS epidemic in low- and middle-income countries (LMICs). The patterns of drug resistance and factors driving emergence of resistance are complex and multifactorial. The key drivers of drug resistance in LMICs are reviewed here, and recommendations are made to limit their influence on antiretroviral therapy efficacy.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/uso terapêutico
Infecções por HIV/tratamento farmacológico
HIV/efeitos dos fármacos
[Mh] Termos MeSH secundário: África ao Sul do Saara/epidemiologia
Países em Desenvolvimento
Farmacorresistência Viral
HIV/genética
Infecções por HIV/epidemiologia
Seres Humanos
Adesão à Medicação
Profilaxia Pós-Exposição
Fatores de Risco
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-HIV Agents)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171222
[Lr] Data última revisão:
171222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix409


  9 / 17474 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29182633
[Au] Autor:Cummins NW; Rizza S; Litzow MR; Hua S; Lee GQ; Einkauf K; Chun TW; Rhame F; Baker JV; Busch MP; Chomont N; Dean PG; Fromentin R; Haase AT; Hampton D; Keating SM; Lada SM; Lee TH; Natesampillai S; Richman DD; Schacker TW; Wietgrefe S; Yu XG; Yao JD; Zeuli J; Lichterfeld M; Badley AD
[Ad] Endereço:Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, United States of America.
[Ti] Título:Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.
[So] Source:PLoS Med;14(11):e1002461, 2017 Nov.
[Is] ISSN:1549-1676
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Notwithstanding 1 documented case of HIV-1 cure following allogeneic stem cell transplantation (allo-SCT), several subsequent cases of allo-SCT in HIV-1 positive individuals have failed to cure HIV-1 infection. The aim of our study was to describe changes in the HIV reservoir in a single chronically HIV-infected patient on suppressive antiretroviral therapy who underwent allo-SCT for treatment of acute lymphoblastic leukemia. METHODS AND FINDINGS: We prospectively collected peripheral blood mononuclear cells (PBMCs) by leukapheresis from a 55-year-old man with chronic HIV infection before and after allo-SCT to measure the size of the HIV-1 reservoir and characterize viral phylogeny and phenotypic changes in immune cells. At day 784 post-transplant, when HIV-1 was undetectable by multiple measures-including PCR measurements of both total and integrated HIV-1 DNA, replication-competent virus measurement by large cell input quantitative viral outgrowth assay, and in situ hybridization of colon tissue-the patient consented to an analytic treatment interruption (ATI) with frequent clinical monitoring. He remained aviremic off antiretroviral therapy until ATI day 288, when a low-level virus rebound of 60 HIV-1 copies/ml occurred, which increased to 1,640 HIV-1 copies/ml 5 days later, prompting reinitiation of ART. Rebounding plasma HIV-1 sequences were phylogenetically distinct from proviral HIV-1 DNA detected in circulating PBMCs before transplantation. The main limitations of this study are the insensitivity of reservoir measurements, and the fact that it describes a single case. CONCLUSIONS: allo-SCT led to a significant reduction in the size of the HIV-1 reservoir and a >9-month-long ART-free remission from HIV-1 replication. Phylogenetic analyses suggest that the origin of rebound virus was distinct from the viruses identified pre-transplant in the PBMCs.
[Mh] Termos MeSH primário: Infecções por HIV/terapia
Carga Viral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Antirretrovirais/uso terapêutico
HIV/genética
Infecções por HIV/virologia
HIV-1/genética
Seres Humanos
Leucócitos Mononucleares
Masculino
Meia-Idade
Filogenia
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia
Transplante de Células-Tronco/métodos
Carga Viral/fisiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Retroviral Agents)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pmed.1002461


  10 / 17474 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29206999
[Au] Autor:Raizes E; Hader S; Birx D
[Ad] Endereço:Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention.
[Ti] Título:Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance.
[So] Source:J Infect Dis;216(suppl_9):S805-S807, 2017 Dec 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The US President's Emergency Plan for AIDS Relief (PEPFAR) supports aggressive scale-up of antiretroviral therapy (ART) in high-burden countries and across all genders and populations at risk toward global human immunodeficiency virus (HIV) epidemic control. PEPFAR recognizes the risk of HIV drug resistance (HIVDR) as a consequence of aggressive ART scale-up and is actively promoting 3 key steps to mitigate the impact of HIVDR: (1) routine access to routine viral load monitoring in all settings; (2) optimization of ART regimens; and (3) routine collection and analysis of HIVDR data to monitor the success of mitigation strategies. The transition to dolutegravir-based regimens in PEPFAR-supported countries and the continuous evolution of HIVDR surveillance strategies are essential elements of PEPFAR implementation.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/uso terapêutico
Infecções por HIV/tratamento farmacológico
Carga Viral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Fortalecimento Institucional
Países em Desenvolvimento
Farmacorresistência Viral/efeitos dos fármacos
HIV/efeitos dos fármacos
Infecções por HIV/virologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix432



página 1 de 1748 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde